Special “Cancers” issue: Targeting STAT3 and STAT5 in cancer

The Special Issue “Targeting STAT3 and STAT5 in Cancer”, edited by Prof. Dr. Richard Moriggl, Prof. Dr. Patrick Gunning and Prof. Dr. György Miklós Keserü was published with 26 papers in Cancers (peer-reviewed Open Access journal of oncology published monthly online by MDPI). Read the full text of the papers at the following link:

Special Issue “Targeting STAT3 and STAT5 in Cancer”

Collaborative paper published in Cancers

Collaborative efforts with the Medical University of Vienna resulted in a new manuscript concerning STAT5 activation in CD34+/CD38 MPN stem cells, published in the journal Cancers. The article is a part of the special issue Targeting STAT3 and STAT5 in Cancer.

STAT5 is Expressed in CD34+/CD38 Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms.
Hadzijusufovic E, Keller A, Berger D, Greiner G, Wingelhofer B, Witzeneder N, Ivanov D, Pecnard E, Nivarthi H, Schur FKM, Filik Y, Kornauth C, Neubauer HA, Müllauer L, Tin G, Park J, de Araujo ED, Gunning PT, Hoermann G, Gouilleux F, Kralovics R, Moriggl R, Valent P.
Cancers (Basel). 2020 Apr 21;12(4). pii: E1021. doi: 10.3390/cancers12041021.

Congratulations to all authors involved!

Collaborative paper published in The Journal of Clinical Investigation

Due to our collaboration with the brilliant researchers at the Technical University of Denmark, we gained novel insights into the role of STAT5 in the programming of innate gamma delta T cells in the neonatal microenvironment. Together, we have now published this study in The Journal of Clinical Investigation. These findings could benefit and contribute to future therapies for human immunological diseases.

The neonatal microenvironment programs innate γδ T cells through the transcription factor STAT5.
Kadekar D, Agerholm R, Rizk J, Neubauer HA, Suske T, Maurer B, Viñals MT, Comelli EM, Taibi A, Moriggl R, Bekiaris V.
J Clin Invest. 2020 Apr 13. pii: 131241. doi: 10.1172/JCI131241. 

Graphical Abstract

Read more about our new insights into immune cell biology relevant for treating human disease at our University press-release page.

We congratulate all involved authors!

Heidi Neubauer is part of the ERA PerMed funded project “JAKSTAT-target”

The project “Novel individualized therapies in JAK/STAT driven T cell malignancies” (Acronym: JAKSTAT-Target) aims to investigate the role of the JAK-STAT pathway in mature T cell lymphomas and to identify potential drugs and drug synergies targeting this pathway.

The consortium of six research groups from Vienna (Heidi Neubauer), Helsinki (Satu Mustjoki, Tero Aittokallio), Cologne (Marco Herling) and Toronto (Patrick Gunning, Benjamin Haibe-Kains) will focus on the entities of T cell prolymphocytic leukemia (T-PLL) and T cell large granular lymphocyte leukemia (T-LGLL), both showing a high incidence of missense mutations in JAK-STAT pathway genes.

The consortium, led by Satu Mustjoki, will uncover new mechanistic insights into these rare diseases and implement machine learning algorithms to predict synergistic effects from genomic, clinical and in vitro drug sensitivity data, ultimately integrating these data into clinical trials.

For more details, please visit the JAK STAT Target Consortium website, the ERA Per Med Newsletter or the affiliated Twitter profile.

March consortium meeting in Helsinki

The Moriggl Lab receives funding within the ERANET Transcan-2 initiative

The project “ERANET-PLL – Implementation of (epi)genetic and metabolic networks in the targeting of T cell prolymphocytic leukemia” was funded within the European ERANET TRANSCAN-2 initiative (Horizon 2020).

The consortium consists of five research groups from Vienna (Richard Moriggl, Philipp Staber), Cologne (Marco Herling), Lyon (Emmanuel Bachy) and Dresden (Ingo Roeder). The consortium, led by Marco Herling, received €1,500,000 in funding, of which €304,720 was allocated to the group in Vienna.

Read more about the ERANET-PLL project.